BMKDF.US BioMark Diagnostics Inc
- Market cap
- USD 34.3M
- P/E
- -
- P/B
- 85.19x
- ROE
- -255.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BMKDF.US undervalued?
Graham numberThe Graham number of BioMark Diagnostics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioMark Diagnostics Inc fundamental analysis
No fundamental analysis for BioMark Diagnostics Inc yet.
BioMark Diagnostics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioMark Diagnostics Inc
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond,…
Full company profileBioMark Diagnostics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioMark Diagnostics Inc annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 263K | 0.00 | 43.9K | 153K | 163K | 154K | 59.8K | 28.0K |
| Gross Profit | 0.00 | 0.00 | 0.00 | 263K | -13.7K | 43.9K | 153K | 163K | - | - | - |
| Operating Income | -721K | -727K | -546K | -1.20M | -1.01M | -1.40M | -1.73M | -1.32M | -1.91M | -1.46M | -1.47M |
| EBITDA | -715K | -727K | -546K | -1.19M | -1.03M | -1.22M | -1.35M | -919K | -1.46M | -1.03M | -964K |
| Net Income | -715K | -727K | -546K | -1.22M | -1.09M | -1.45M | -1.84M | -1.43M | -1.93M | -1.48M | -1.46M |
| EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 39.6K | 51.7K | 34.6K | 637K | 953K | 1.47M | 732K | 1.09M | 3.13M | 1.86M | 2.17M |
| Total Liabilities | 1.10M | 952K | 1.25M | 1.08M | 1.03M | 2.11M | 1.88M | 1.70M | 1.39M | 1.53M | 1.60M |
| Shareholders' Equity | -1.07M | -900K | -1.22M | -439K | -79.1K | -636K | -1.15M | -610K | 1.74M | 331K | 571K |
| Cash & Short-term Investments | 17.5K | 36.6K | 20.0K | 612K | 878K | 383K | 72.0K | 157K | 2.48M | 619K | 730K |
| Total Debt | - | - | - | 8.66K | 119K | 1.05M | 824K | 806K | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -110K | -770K | -278K | -454K | -807K | -1.20M | -914K | -983K | -1.09M | -1.09M | -1.04M |
| Capital Expenditure | 1.64K | 1.64K | 790.00 | 790.00 | 59.2K | 59.2K | 5.30K | 4.39K | 3.53K | 4.23K | 0.00 |
| Free Cash Flow | -110K | -772K | -278K | -455K | -807K | -1.26M | -920K | -987K | -1.10M | -1.09M | -1.04M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | - | - | - | -110.7% | -446.2% | -255.1% |
| ROA | -1,807.9% | -1,404.5% | -1,575.0% | -190.7% | -114.8% | -98.8% | -251.6% | -131.1% | -61.5% | -79.4% | -67.3% |
| Net Profit Margin | - | - | - | -461.6% | - | -3,309.4% | -1,200.2% | -874.5% | -1,249.7% | -2,470.8% | -5,198.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioMark Diagnostics Inc dividends
BioMark Diagnostics Inc has not paid dividends in the last 9 fiscal years.
Who owns BioMark Diagnostics Inc
- Insiders 48.52%
- Institutions 0.00%
- Public & others 51.48%
- Shares outstanding 106M
- Free float 48.9M
BioMark Diagnostics Inc company profile
- Company name
- BioMark Diagnostics Inc
- Ticker
- BMKDF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- March
- Address
- 3851 Shell Road, Richmond, BC, Canada, V6X 2W2
- Phone
- 604-370-0779
- Website
- biomarkdiagnostics.com
About BioMark Diagnostics Inc
Biomark Diagnostics Inc. develops early-stage cancer diagnostic technology platform to detect and treat cancer. The company invests in and develops a liquid biopsy metabolic panel assay for the early-stage diagnosis of lung cancer and glioblastoma (GBM) breast cancer. It is also developing liquid biopsy tests for various cancer types, including glioblastoma, gastrointestinal, prostate, head, neck cancers. The company was incorporated in 2014 and is headquartered in Richmond, Canada.
BioMark Diagnostics Inc management
4- Mr. Rashid Ahmed Maula Bux B.Sc., MBAFounder, CEO, President & Director
- Ms. Guoyu Huang MBAChief Financial Officer
- Mr. Brian Kai-Ming Cheng B.Sc., M.Sc.Chief Technical Officer & Independent Director
- Dr. Jean-Francois Haince Ph.D.GM & Chief Scientific Officer